ImmuCell Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- F. Olivier Te Boekhorst
- Full Time Employees
- 73
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 56 Evergreen Drive Portland ME United States of America 04103
- IPO Date
- May 5, 1987
- CIK
- 0000811641
- Website
- immucell.com
- Similar Companies
- Business
- ImmuCell Corporation (Nasdaq: ICCC), an animal health company founded in 1982 and headquartered at 56 Evergreen Drive in Portland, Maine, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle primarily in the United States, Canada and select international markets including South Korea and the Middle East. The company operates through two main segments, Scours and Mastitis, with its flagship First Defense product line offering USDA-licensed, orally delivered scours preventives for newborn calves and lambs, including First Defense with claims against E. coli, coronavirus and rotavirus; Tri-Shield First Defense, a passive antibody gel tube product providing immediate immunity against E. coli, coronavirus and rotavirus and approved for organic farms; Dual-Force First Defense, a bivalent gel tube formulation; and First Defense Technology, a colostrum concentrate in bulk powder and gel formats for nutritional supplementation without USDA disease claims. Additional products include the California Mastitis Test, a rapid on-farm diagnostic for detecting somatic cell counts and udder infections in dairy cows. ImmuCell sells these products through animal health distributors, veterinarians, fleet stores and directly to producers, targeting the approximately $82 million U.S. calf-level and dam-level scours prevention market where it holds leading share in calf-level treatments. In recent developments, the company increased First Defense production capacity beyond $30 million annually through facility expansions and new equipment completed by late 2022, overcame product contamination events resolved by mid-2024 with no recurrences since April 2024, reported Q2 2025 product sales up 18% to $6.4 million with gross margins improving to 44% from 22%, refinanced $2.33 million in bank debt at 6.5% interest with Maine Community Bank to eliminate $1.95 million in balloon payments due in 2026 and extend terms to 2030, raised approximately $4.6 million through an at-the-market equity offering of 1.2 million shares during 2024, submitted the final Technical Section of its New Animal Drug Application for Re-Tain—a purified Nisin intramammary treatment for subclinical mastitis without milk discard requirements—in January 2025 pending FDA approval on four of five sections, and initiated investigational product use of Re-Tain in the second half of 2025 to test market acceptance while evaluating further capacity expansions up to $40 million to meet North American demand. Cumulative First Defense sales exceeded 36 million doses by late 2024, reflecting sustained growth despite prior supply constraints, with ongoing efforts to penetrate beef markets, expand international registrations and launch lower-cost spray-dried formats.
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
ImmuCell Q1 Earnings Call Highlights
ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Here’s Why
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
ImmuCell Q4 Earnings Call Highlights
ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve
ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
ImmuCell (NASDAQ:ICCC) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?
Niche Focus & Regulation Shape the Future of Healthcare Firms